Conversion ratios for opioid switching in the treatment of cancer pain: a systematic review
- 27 June 2011
- journal article
- review article
- Published by SAGE Publications in Palliative Medicine
- Vol. 25 (5) , 504-515
Abstract
In this paper we describe the results of a systematic search of the literature on conversion ratios during opioid switching. This is part of a project of the European Palliative Care Research Collaboration to update the European Association for Palliative Care recommendations for the use of opioid analgesics in the treatment of cancer pain. Studies were eligible for inclusion if they involved adult patients with chronic cancer pain, contained data on opioid conversion ratios, were prospective and were written in English. Thirty-one studies were identified and included. The majority of the studies had methodological flaws and were not designed to explore or demonstrate equianalgesic dose data. However, the data allow some recommendations to be made that could be helpful to clinicians for whom there are few reliable experimental data on which to base dosing guidelines. Switching to transdermal fentanyl (TDfe) or buprenorphine (TDbu) is an option for patients with stable, controlled pain. Reliable and consistent studies show a ratio of 100 : 1 between oral morphine (ORmo) and TDfe. A ratio of 75 : 1 between ORmo and TDbu may be appropriate, but the supporting evidence here is much less robust. Data are relatively consistent to support a conversion ratio between ORmo and oral hydromorphone (ORhy) of 5 : 1. Despite some limitations, there is evidence to support the use of an approximate conversion ratio of ORmo:oral oxycodone (ORox) of 1.5 : 1. The conversion between ORox and ORhy is estimated to be 1 : 4. When switching from different opioids to methadone the conversion ratio is highly variable, ranging from 5 : 1 to 10 : 1 and much higher in some studies. The derived ratios are influenced by several factors, including the reasons for switching and previous opioid doses. An individual treatment decision and strict monitoring is recommended for patients considered at risk.Keywords
This publication has 51 references indexed in Scilit:
- Establishing “Best Practices” for Opioid Rotation: Conclusions of an Expert PanelJournal of Pain and Symptom Management, 2009
- Opioid Rotation: The Science and the Limitations of the Equianalgesic Dose TableJournal of Pain and Symptom Management, 2009
- Opioid switching and rotation in primary care: implementation and clinical utilityCurrent Medical Research and Opinion, 2009
- GRADE: an emerging consensus on rating quality of evidence and strength of recommendationsBMJ, 2008
- Opioid switching: A systematic and critical reviewCancer Treatment Reviews, 2006
- Morphine and alternative opioids in cancer pain: the EAPC recommendationsBritish Journal of Cancer, 2001
- Opioid Poorly-Responsive Cancer Pain. Part 2Journal of Pain and Symptom Management, 2001
- Opioid rotation for cancer painCancer, 1999
- Opioid rotation in patients with cancer pain: A retrospective comparison of dose ratios between methadone, hydromorphone, and morphineCancer, 1996
- Opioid rotation for toxicity reduction in terminal cancer patientsJournal of Pain and Symptom Management, 1995